2008-07-02 18:55:17 - www.companiesandmarkets.com adds new report - ACADIA Pharmaceuticals Inc. -Premium Company Profile

www.companiesandmarkets.com/Summary-Company-Profile/ACADIA-Pharm ..
Introduction

ACADIA Pharmaceuticals is a clinical development stage biopharmaceutical company mainly focused on discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system (CNS) disorders utilizing its innovative R-SAT functional assay technology.



Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key

competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies


Highlights

ACADIA Pharmaceuticals has a pipeline of drug candidates including: Pimavanserin, as a co-therapy for schizophrenia and for the treatment of Parkinson´s disease psychosis; ACP-104, for treatment of schizophrenia; and a neuropathic pain program in Phase II development in collaboration with Allergan.



It derives 100% of its revenues from research and milestone payments under its collaboration agreements with strategic partners Allergan, Sepracor and The Stanley Medical Research Institute for the development of new drug candidates and therapeutics. During 2002-2006, it´s total revenues increased at a CAGR of 7%, from $6 million to $8 million.



Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization